Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of PAN-90806 Eye Drops in Healthy Subjects
NCT07764965Phase 1Not yet recruiting
- Sponsor
- Zhaoke Ophthalmology
- Start
- Sep 2026
- Primary completion
- Dec 2026
01
Overview
Phase 1, randomised, double-blind trial in exudative macular degeneration comparing PAN-90806 Eye Drops with Vehicle Eye Drops (2 arms). Primary endpoints: Corneal endothelial cell density at Day 9, Corneal endothelial cell coefficient of variation at Day 9 and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
PAN-90806
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT07764965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764965.